relugolix or androgen deprivation therapy (ADT) + ARPI
Phase 2
relugolix or androgen deprivation therapy (ADT) + ARPI is one of 6 therapeutic programs targeting Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Metastatic Hormone-Sensitive Prostate Cancer (mhspc)
#DrugCompanyPhaseTrials
1Orgovyx
Sumitomo Pharma America, Inc.Phase 2
Nubeqa
BayerPhase 1
Zytiga
Johnson & JohnsonPhase 1
Xaluritamig
AmgenPhase 1
Tulmimetostat
NovartisPreclinical
relugolix or androgen deprivation therapy (ADT) + ARPI
UUniversity of Utah
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Utah